Use of accumulation images obtained by arterial-phase contrast-enhanced harmonic grayscale ultrasonography to evaluate tumor vessels in focal nodular hyperplasia and other hepatic tumors

2007 ◽  
Vol 34 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Kazushi Numata ◽  
Manabu Morimoto ◽  
Tetsuo Isozaki ◽  
Kazuya Sugimori ◽  
Hiroyuki Oka ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Phase Contrast ◽  
Arterial Phase ◽  
Hepatic Tumors ◽  
Tumor Vessels ◽  
Contrast Enhanced ◽  
Nodular Hyperplasia

Baseline and contrast-enhanced ultrasound features of hepatic epithelioid angiomyolipoma

2021 ◽  
pp. 1-15
Author(s):  
Pei-Li Fan ◽  
Zheng-Biao Ji ◽  
Jia-Ying Cao ◽  
Chen Xu ◽  
Yi Dong ◽  
...  
Keyword(s):  
Resistive Index ◽  
Malignant Potential ◽  
Arterial Phase ◽  
Hepatic Tumors ◽  
Contrast Enhanced Ultrasound ◽  
Uncertain Malignant Potential ◽  
Epithelioid Angiomyolipoma ◽  
Tumor Vessels ◽  
Contrast Enhanced ◽  
Ultrasound Features

BACKGROUND: Recurrence or metastasis after surgery had been reported in hepatic epithelioid angiomylipoma (epi-AML). Most hepatic epi-AMLs were misdiagnosed with hepatocellular carcinoma or other hepatic tumors before surgery. OBJECTIVE: To describe the baseline and contrast-enhanced ultrasound (CEUS) features of hepatic epi-AMLs and to explore the potential ultrasonic features for prognosis. METHODS: The retrospective study enrolled 67 patients (56 females, 11 males) with 67 pathologically confirmed hepatic epi-AML lesions. All the lesions were examined by baseline ultrasound and 42 lesions were examined using CEUS with SonoVue (Bracco, Milan, Italy) before surgery. RESULTS: Baseline ultrasound features of hepatic epi-AMLs included heterogeneous echo (86.6%), well-defined border (68.7%), hypoecho (64.2%), regular morphology (62.7%), peripheral-tumor arc-shaped or ring-like vessels (53.7%), and low value of resistive index (0.51±0.08). CEUS features of hepatic epi-AMLs included arterial phase hyper-enhancement with smooth and well-defined margin (100%), peripheral-tumor ring-like vessels (57.1%), and intra-tumor vessels (52.4%). Some CEUS features, including arterial phase heterogeneously tortuous filling, intra-tumor vessels and peripheral-tumor ring-like vessels were more commonly found in hepatic epi-AMLs of uncertain malignant potential/malignant than in benign hepatic epi-AMLs (p <  0.05). CONCLUSIONS: Baseline ultrasound and CEUS features may be useful in diagnosis of hepatic epi-AML, and some CEUS features may be indicative of its malignant potential.

An MR-Based Radiomics Model for Differentiation Between Hepatocellular Carcinoma and Focal Nodular Hyperplasia in Non-Cirrhotic Liver

2021 ◽  
Author(s):  
Zongren Ding ◽  
Kongying Lin ◽  
Jun Fu ◽  
Qizhen Huang ◽  
Guoxu Fang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Focal Nodular Hyperplasia ◽  
Cirrhotic Liver ◽  
Arterial Phase ◽  
Training Set ◽  
Combined Model ◽  
Clinical Model ◽  
Contrast Enhanced ◽  
Nodular Hyperplasia ◽  
Validation Set

Abstract Purpose:This study aimed to develop and validate a radiomics model for differentiating between hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) in non-cirrhotic livers using Gd-DTPA contrast-enhanced magnetic resonance imaging (MRI).Methods:We retrospectively enrolled 149 HCC patients and 75 FNH patients seen between May 2015 and May 2019 at our center and randomly allocated patients to a training set (n = 156) and a validation set (n = 68). A total of 2,260 radiomics features were extracted from the arterial phase and portal venous phase of Gd-DTPA contrast-enhanced MRI. Using Max-Relevance and Min-Redundancy, random forests, and the least absolute shrinkage and selection operator algorithm for dimensionality reduction, multivariable logistic regression was used to build the radiomics model. A clinical model and combined model were also established. The diagnostic performance of the three models was compared. Results:Eight radiomics features were chosen to build a radiomics model, and four clinical factors (age, sex, HbsAg, and enhancement pattern) were chosen to build the clinical model. When evaluating the performance of three models, the clinical model that included clinical data and visual MRI findings achieved excellent performance in the training set (AUC, 0.937; 95% CI, 0.887–0.970) and the validation set (AUC, 0.903; 95% CI, 0.807–0.962), and there was no significant difference between the radiomics model and the clinical model. The AUC of the combined model was significantly better than that of the clinical model for both the training (0.984 vs. 0.937, p = 0.002) and validation (0.972 vs. 0.903, p = 0.032) sets.Conclusions:The combined model based on clinical and radiomics features can well distinguish HCC from FNH in non-cirrhotic liver. Our model may assist clinicians in the clinical decision-making process.

scholarly journals An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zongren Ding ◽  
Kongying Lin ◽  
Jun Fu ◽  
Qizhen Huang ◽  
Guoxu Fang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Focal Nodular Hyperplasia ◽  
Clinical Decision Making ◽  
Cirrhotic Liver ◽  
Arterial Phase ◽  
Combined Model ◽  
Clinical Model ◽  
Portal Venous Phase ◽  
Contrast Enhanced ◽  
Nodular Hyperplasia

Abstract Purpose We aimed to develop and validate a radiomics model for differentiating hepatocellular carcinoma (HCC) from focal nodular hyperplasia (FNH) in non-cirrhotic livers using Gd-DTPA contrast-enhanced magnetic resonance imaging (MRI). Methods We retrospectively enrolled 149 HCC and 75 FNH patients treated between May 2015 and May 2019 at our center. Patients were randomly allocated to a training (n=156) and validation set (n=68). In total, 2260 radiomics features were extracted from the arterial phase and portal venous phase of Gd-DTPA contrast-enhanced MRI. Using Max-Relevance and Min-Redundancy, random forest, least absolute shrinkage, and selection operator algorithm for dimensionality reduction, multivariable logistic regression was used to build the radiomics model. A clinical model and combined model were also established. The diagnostic performance of the models was compared. Results Eight radiomics features were chosen for the radiomics model, and four clinical factors (age, sex, HbsAg, and enhancement pattern) were chosen for the clinical model. A combined model was built using the factors from the previous models. The classification accuracy of the combined model differentiated HCC from FNH in both the training and validation sets (0.956 and 0.941, respectively). The area under the receiver operating characteristic curve of the combined model was significantly better than that of the clinical model for both the training (0.984 vs. 0.937, p=0.002) and validation (0.972 vs. 0.903, p=0.032) sets. Conclusions The combined model provided a non-invasive quantitative method for differentiating HCC from FNH in non-cirrhotic liver with high accuracy. Our model may assist clinicians in the clinical decision-making process.

scholarly journals Contrast-enhanced ultrasound for the assessment of focal nodular hyperplasia – results of a multicentre study

2021 ◽  
Author(s):  
Roxana Şirli ◽  
Ioan Sporea ◽  
Alina Popescu ◽  
Mirela Dănilă ◽  
Daniela Larisa Săndulescu ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Predictive Value ◽  
De Novo ◽  
Arterial Phase ◽  
Mechanical Index ◽  
Contrast Enhanced Ultrasound ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Nodular Hyperplasia

Aim: Contrast-enhanced ultrasound (CEUS) has become a relevant imaging method for the evaluation of focal liver le-sions (FLL). The aim of this study was to evaluate the performance of CEUS for the assessment of focal nodular hyperplasia (FNH) in a large study group. Material and methods: We performed a multicentre prospective observational study, which included successive CEUS examinations from fourteen Romanian centres. CEUS examinations were performed in de novo FLL, using low mechanical index ultrasound, following an intravenous bolus of 2.4 ml SonoVue. CEUS was considered conclusive for FNH if a typical pattern was present following contrast (rapid “spoke-wheel” enhancement during the arterial phase, hyperenhanced lesion during venous phase, hyper- or isoenhanced in the late phase). In all cases a reference method was available (contrast enhanced CT or MRI or biopsy). The trial was registered in clinicaltrials.gov (Identifier NCT01329458). Results: During the 6 years study, 2062 “de novo” FLL were evaluated by CEUS. From this cohort, 94/2062 (4.5%) had a typical enhancing pattern for FNH as described in the EFSUMB guidelines. Contrast enhanced CT/MRI and biopsy diagnosed additional 15 FNH. From the 94 cases diagnosed as FNH by CEUS, in nine the final diagnosis was different (five of them adenomas). CEUS had 85% sensitivity, 99.5% specificity, 90.4% positive predictive value, 99.2% negative predictive value and 98.8% diagnostic accuracy for the diagnosis of FNH. Conclusions: CEUS is a sensitive and very specific method for the diagnosis of FNH.

Contrast-enhanced ultrasonography using levovist: Usefulness of diagnosis of small focal nodular hyperplasia lesions

2002 ◽  
Vol 29 (3) ◽  
pp. 99-104 ◽  
Author(s):  
Yoshiaki Miura ◽  
Koryo Kondo ◽  
Junko Oikawa ◽  
Hidekatsu Kuroda ◽  
Kazuhiro Kasai ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Contrast Enhanced ◽  
Nodular Hyperplasia ◽  
Contrast Enhanced Ultrasonography

Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia

2006 ◽  
Vol 60 (3) ◽  
pp. 439-444 ◽  
Author(s):  
Yi-Hao Yen ◽  
Jing-Houng Wang ◽  
Sheng-Nan Lu ◽  
Tai-Yi Chen ◽  
Chi-Sin Changchien ◽  
...  
Keyword(s):  
Focal Nodular Hyperplasia ◽  
Contrast Enhanced ◽  
Nodular Hyperplasia
Sign in / Sign up

Export Citation Format

Share Document